Alnylam Pharmaceuticals revenue and financials
$223.94Change from previous close: +1.84%Absolute change: +$4.05
In the fiscal year ended December 2025, Alnylam Pharmaceuticals reported revenue of $3.71B (+65.19% year over year). Net income was $313.75M, a net margin of 8.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +65.19%
- 2025 vs 2024
- Net margin
- 8.4%
- 2024: -12.4%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 524 | -8.3 | 104 | -541 | -642 | -615 | -278 | -563 | -383 | -308 |
| Depreciation and amortization | 55.7 | 56.7 | 54.1 | 44.5 | 47.6 | 34.8 | 17.2 | 15.2 | 13.4 | 15.1 |
| Capital expenditure | -58.7 | -34.3 | -62.2 | -72.1 | -76.4 | -70.4 | -140 | -127 | -104 | -64.6 |
| Investing cash flow | 436 | -117 | -336 | 169 | -273 | — | — | — | — | — |
| Financing cash flow | -305 | 294 | 172 | 426 | 1,247 | — | — | — | — | — |
| Debt issued | 646 | 0.0 | 0.0 | 1,016 | — | — | — | — | — | — |
| Debt repaid | -1,190 | 0.0 | 0.0 | -762 | — | — | — | — | — | — |
| Effect of exchange rates | 34.9 | -15.2 | 6.4 | -7.4 | -9.0 | — | — | — | — | — |
| Net change in cash | 690 | 154 | -53.7 | 46.4 | 323 | — | — | — | — | — |
| Free cash flow | 465 | -42.6 | 41.9 | -613 | -718 | — | — | — | — | — |
| Levered free cash flow | 129 | 198 | 104 | -444 | 97.1 | — | — | — | — | — |